{"id":"W2326074019","doi":"10.1177/095632020401500302","title":"Clinical Utility of Current NNRTIs and Perspectives of New Agents in This Class under Development","year":2004,"lang":"en","type":"review","venue":"Antiviral chemistry & chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Valeant Pharmaceuticals International; Bristol-Myers Squibb; Boehringer Ingelheim","keywords":"Nucleoside Reverse Transcriptase Inhibitor; Reverse transcriptase; Dosing; Protease inhibitor (pharmacology); Virology; Reverse-transcriptase inhibitor; Pharmacology; Human immunodeficiency virus (HIV); ANTIRETROVIRAL AGENTS; Medicine; Biology; Antiretroviral therapy; Viral load; Genetics; RNA","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001602942,0.0009400034,0.001665676,0.002123085,0.000344586,0.001324342,0.001080507,0.001537523,0.004596867],"category_scores_gemma":[0.001108609,0.0003095138,0.0006096317,0.001876437,0.0005591611,0.001832412,0.0004811124,0.001616835,0.003150593],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006607538,"about_ca_system_score_gemma":0.001195795,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008641964,"about_ca_topic_score_gemma":0.001938802,"domain_scores_codex":[0.9994331,0.0001134296,0.00007363076,0.00008630601,0.0002537183,0.00003972093],"domain_scores_gemma":[0.9994221,0.0002105392,0.0001017806,0.00002690518,0.0001899467,0.00004889297],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001401861,0.00008775844,0.0003044179,0.009101871,0.00007043879,0.0003959895,0.00007742579,0.0004107221,0.003794651,0.004025236,0.01049657,0.9710947],"study_design_scores_gemma":[0.00004810744,0.0002693067,0.001153752,0.00277969,0.0001066159,0.002536305,0.00009416968,0.0001462646,0.001210768,0.002765334,0.9888703,0.00001954015],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001786752,0.9977901,0.0001297553,0.0002709304,0.0001187848,0.000004369091,0.00001053576,0.000004065587,0.001492722],"genre_scores_gemma":[0.001241339,0.9968519,0.0004103827,0.0002296609,0.0002084075,0.000008825811,0.00002618083,0.000001597218,0.00102183],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.004596867,"threshold_uncertainty_score":0.015378,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1243724358799134,"score_gpt":0.4137304869345004,"score_spread":0.289358051054587,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}